Why wearing a tampon while working out may not be great for your health
No sweat!
Experts say exercising on your period is absolutely fine — and even beneficial — because hitting the gym can reduce menstrual pain, boost mood and potentially ease bloating.
If you're planning to embrace outdoor workouts this summer, you may want to take extra care choosing feminine products that offer protection while also helping to manage sweat, odor and chafing.
Advertisement
4 Hitting the gym can reduce menstrual pain, boost mood and potentially ease bloating.
Getty Images/iStockphoto
Though it is generally safe to exercise while wearing a tampon, the founder and CEO of the nontoxic, sustainable period care brand Viv For Your V warns of a possible hygiene issue with sweaty, high-impact activity.
'Sweat tends to accumulate around the vagina and underwear, creating a damp environment, causing the tampon string to become wet,' Katie Diasti told The Post. 'A wet string can lead to an increase in bacterial growth and higher risk of UTIs and yeast infections.'
Advertisement
Pads, menstrual cups, discs or athletic period underwear may be better options.
For their part, tampons have come under fire recently due to concerns about their safety and potential health risks.
A shocking 2024 study found lead, arsenic and other toxic heavy metals in several tampon brands, prompting an investigation by the Food and Drug Administration.
4 Though it is generally safe to exercise while wearing a tampon, one menstrual brand CEO warns of a potential hygiene issue with sweaty, high-impact activity.
Pixel-Shot – stock.adobe.com
Advertisement
The agency's initial literature review didn't identify safety concerns with tampon use and contaminant exposure.
The FDA is also conducting laboratory tests to determine if metals are released from tampon materials into the body.
Dr. Alessandra Hirsch, an OB/GYN at NewYork-Presbyterian/Columbia University Irving Medical Center, pointed out that the 2024 study didn't explore whether the metals were absorbed through the vaginal lining.
Advertisement
'A substance is only 'toxic' if it reaches vital organs in a high enough quantity to cause harm, which this paper did not investigate,' Hirsch told The Post.
'The American College of Medical Toxicology released a statement last year in response to this paper to reassure menstruating individuals that there is still no evidence that tampons cause metal poisoning.'
4 A shocking 2024 study found lead, arsenic and other toxic heavy metals in several tampon brands, prompting an investigation by the Food and Drug Administration.
¿¿¿¿¿ ¿¿¿¿¿¿¿¿ – stock.adobe.com
As its investigation carries on, the FDA 'continues to recommend FDA-cleared tampons as a safe option' for menstrual use.
'Much more study and research is required, and there are currently no recommendations to not use tampons,' Dr. Mitchell Kramer, director of obstetrical and gynecologic strategy and clinical integration at Northwell's Huntington Hospital, told The Post.
'There are certain ways to minimize risk,' he added. 'Use 100% organic cotton tampons that do not contain any dyes or fragrances, avoid synthetic fiber tampons, change tampons frequently (this also minimizes the risk of toxic shock syndrome), and use tampons for the minimum amount of time that is comfortable during the period.'
Toxic shock syndrome (TSS) is a rare but potentially life-threatening illness caused by bacterial toxins.
Advertisement
A tampon left in too long can become a breeding ground for bacteria that cause TSS, bacterial vaginosis and vaginal yeast infections.
4 This summer, you should take extra care choosing feminine products that offer protection while also helping to manage sweat, odor and chafing.
zakalinka – stock.adobe.com
The FDA recommends changing tampons every four to eight hours to maintain good hygiene and reduce the risk of bacterial growth and TSS.
Advertisement
That's why tampons might not be the best choice while sleeping, hiking and playing outside for a long time, Diasti said.
'These situations can make it harder to change your tampon on time,' she added. 'Menstrual cups and discs are great alternatives — they offer longer wear time and greater convenience for extended periods without access to a restroom.'
Menstrual discs are designed to sit in the space behind the cervix, while menstrual cups are typically positioned just below the cervix.
The cup must fit well. Diasti said a wrong-fitting cup can leak or shift during physical activity, especially for those with a high or low cervix.
Advertisement
Hirsch warns that an improperly cleaned menstrual cup may increase the risk of fungal infections, while pads or period underwear can cause local allergic reactions such as rashes and itching.
'All of this is to say that, unfortunately, manufactured products all carry some unknown risk, which we believe to be quite small,' Hirsch said. 'For now, the best way to decide on a period product is to pick the best fit for your lifestyle.'
If none of these options work for you, there's always free bleeding.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
8 minutes ago
- Washington Post
The young adults living with cancer
Shay and Tanner Martin open gifts at their baby shower in Provo, Utah, on April 12. In 2020, Tanner was diagnosed with Stage 4 colon cancer (Jahi Chikwendiu/The Washington Post) Since 2000, the rate of new cancer diagnoses for people ages 15 to 49 has climbed by 10 percent. This year, more than 200,000 people in that age group will be newly diagnosed with cancer. They will join more than 2.1 million Americans who were also diagnosed as young adults and are living with the today's episode, Post video journalist Drea Cornejo sits down with host Elahe Izadi to talk about how Drea's own cancer diagnosis three years ago, when she was 26, motivated her to report on the realities facing more younger adults. Drea documented the lives of Tanner and Shay Martin over the past six months as they navigated Tanner's terminal colon cancer diagnosis with big life decisions including starting a family. While most young adults survive their cancer diagnosis, they still face the potential of a greatly altered future with implications for relationships, careers, finances and family planning. You can watch The Post's short documentary about Tanner and Shay here. Be sure to also check out the comic about Drea's diagnosis here. Today's show was produced by Elana Gordon. It was mixed by Ted Muldoon and edited by Renita Jablonski with additional editing by Lynh Bui, Mary-Ellen Deily and Dan Keating. Additional reporting for this story came from Dan Keating, Ariana Cha and Julia Wall. Special thanks to Wendy Galietta, Whitney Leaming, Jessica Koscielniak and Stephen Smith. Subscribe to The Washington Post here
Yahoo
4 hours ago
- Yahoo
U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET PRINCETON, N.J., June 12, 2025--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen's proprietary sustained release RTGel® technology. ZUSDURI has been designed for potent tumor ablation. This landmark approval is based on the positive results from the Phase 3 ENVISION trial that demonstrated ZUSDURI delivers 78% complete response (CR) for patients at 3 months, and of those patients 79% remained event-free 12 months later. "The approval of ZUSDURI represents a significant step forward for our company and for the treatment of recurrent LG-IR-NMIBC," said Liz Barrett, President and CEO of UroGen. "For the first time, the estimated 59,000 U.S. patients facing recurrent LG-IR-NMIBC each year have access to an FDA-approved medicine. This historic achievement is a bold leap forward in our mission to redefine uro-oncology and bring innovation to patients who need it most. We are deeply grateful to the FDA for their collaboration and to the investigators, patients, and caregivers whose commitment made this milestone possible. Their contributions have been essential in bringing meaningful innovation to the bladder cancer community." The existing standard of care for LG-IR-NMIBC is a surgical procedure typically performed under general anesthesia called transurethral resection of bladder tumor (TURBT). Due to high recurrence rates of LG-IR-NMIBC, repeat TURBTs may be necessary. "ZUSDURI marks a breakthrough in uro-oncology, offering a new alternative for recurrent LG-IR-NMIBC patients who can live for many years with the disease but often endure multiple resections, under general anesthesia," said Dr. Sandip Prasad, MD, Director of Genitourinary Surgical Oncology at Morristown Medical Center/Atlantic Health System, NJ, and principal investigator of the ENVISION trial. "For decades, TURBT has been the standard approach for bladder cancer treatment. That's why innovative treatments like ZUSDURI are essential, especially for those adult patients with recurrent low-grade, intermediate-risk NMIBC." The most common (≥ 10%) adverse reactions, including laboratory abnormalities, that occurred in patients were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. Serious adverse reactions occurred in 12% of patients who received ZUSDURI, including, urinary retention (0.8%) and urethral stenosis (0.4%). Product Availability ZUSDURI is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. In the interim, patients can visit (available soon). UroGen Patient Support UroGen is committed to helping patients access ZUSDURI. UroGen Support may help identify appropriate financial assistance programs for eligible patients with commercial, Medicare or Medicaid coverage, as well as those with no insurance coverage. These programs are for eligible patients who have been prescribed ZUSDURI and who need help managing the cost of treatment. The appropriate program will depend on the patient's insurance coverage. Visit (available soon) or contact UroGen Support at 1-833-UROGEN-1 (1-833-876-4361) for additional information. Post-Marketing Commitment As a post-marketing commitment, UroGen has agreed with the FDA to complete the ongoing ENVISION trial to further characterize the clinical benefit of ZUSDURI for the treatment of patients with recurrent LG-IR-NMIBC. In addition, UroGen committed to provide the FDA annual updates on duration of response (DOR) for all patients with ongoing complete responses. The annual updates will continue until all ongoing patients experience a recurrence of LG-IR-NMIBC; progression; death; loss to follow-up; or reach 63 months after the first instillation as planned in the protocol, whichever occurs first. Conference Call & Webcast Information Members of UroGen's management team will host a live conference call and webcast on June 13, 2025 at 8:30 AM Eastern Time to review ZUSDURI approval details and commercialization plans. The live webcast can be accessed by visiting the Investors section of the Company's website at Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. An archive of the webcast will be available on the Company's website. About ZUSDURI ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel® technology, a sustained release, hydrogel-based formulation, ZUSDURI is delivered directly into the bladder in an out-patient procedure by a trained healthcare professional using a urinary catheter to enable the treatment of tumors by non-surgical means. About Non-Muscle Invasive Bladder Cancer (NMIBC) LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and ZUSDURI (mitomycin) for intravesical solution, UroGen's first product to treat recurrent LG-IR-NMIBC are both designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X, @UroGenPharma. APPROVED USE FOR ZUSDURI ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working. IMPORTANT SAFETY INFORMATION You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI. Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose. How will I receive ZUSDURI? You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI: ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information. ZUSDURI™ is a trademark and UroGen® is a registered trademark of UroGen Pharma, Ltd. Copyright©2025 UroGen Pharma, Inc. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for ZUSDURI; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as "can," "expect," "may," "plan," "potential," "target," "will" or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; UroGen's RTGel technology and ZUSDURI may not perform as expected; new data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market; the potential for payors to delay, limit or deny coverage for ZUSDURI; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025. The events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. View source version on Contacts INVESTOR CONTACT:Vincent PerroneSenior Director, Investor 609-460-3588 ext. 1093 MEDIA CONTACT:Cindy RomanoDirector, Corporate 609-460-3583 ext. 1083
4 hours ago
Some Dr Pepper Zero soda recalled for having 'full sugar'
Hundreds of thousands of cans of Dr Pepper Zero soda are being recalled because they're incorrectly labeled as a zero-sugar product when it's actually a 'full sugar product,' according to a report from the Food and Drug Administration (FDA). The recall affects 19,203 cases of 12 packs and 24 packs of Dr Pepper Zero Sugar 12-ounce cans that were distributed to Florida, Georgia and South Carolina. The voluntary recall was first initiated on May 23. On June 5, the FDA classified it as a Class II recall. According to the FDA, a product under a Class II recall may lead to 'temporary or medically reversible adverse health consequences" or a situation "where the probability of serious adverse health consequences is remote.' Sugary drinks can be harmful to anyone, especially if they drink large amounts. People who are at risk of certain conditions such as heart disease, high blood pressure, obesity and type 2 diabetes may want to avoid added sugars like those in sodas, which may contribute to the conditions, according to the Centers for Disease Control and Prevention. A Dr Pepper Zero soda is typically made with aspartame, a sugar substitute, instead of sugar. Recalled soda cans have a "best by" date of Feb. 16, 2026. When reached by ABC News, Dr Pepper's parent company, Keurig Dr Pepper, said recalled cans of soda were produced by a PepsiCo bottling facility that is licensed to make some Keurig Dr Pepper products and that the recalled product has been removed from stores. The beverage company also did not indicate if it received any reports of people impacted by the recall.
